Sulforaphane for Chronic Kidney Disease
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are on anticoagulants (blood thinners) or immunosuppression (medications that lower the immune system).
What data supports the effectiveness of the treatment Sulforaphane (Avmacol Extra Strength) for Chronic Kidney Disease?
Research suggests that sulforaphane, found in certain vegetables, may help protect kidneys by reducing inflammation and oxidative stress (damage caused by free radicals) in preclinical models of kidney diseases. However, specific data on its effectiveness in chronic kidney disease patients is limited.12345
Is sulforaphane safe for humans?
How is the treatment sulforaphane unique for chronic kidney disease?
Sulforaphane is unique for chronic kidney disease because it is a natural compound found in cruciferous vegetables that activates the Nrf2 pathway, which helps protect cells from oxidative stress and inflammation. This approach is different from standard treatments as it uses a dietary component to potentially improve kidney health.13458
What is the purpose of this trial?
The Sulforaphane Production System® in Avmacol Extra Strength (ES) supplies broccoli seed extract (glucoraphanin) and Myrosimax® (Active Myrosinase Enzyme) which helps promote sulforaphane production in your body. The investigators hypothesize that daily intake of Avmacol ES can decrease kidney disease progression rate and decrease markers of oxidative stress and inflammation in Chronic Kidney Disease (CKD) patients. They will test this hypothesis in a randomized, double-blind, placebo controlled Phase 2 clinical trial. This proposed study has been funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), R01 DK128677.
Eligibility Criteria
Adults aged 18-80 with moderate chronic kidney disease, specifically those whose kidneys are filtering at a reduced rate and have shown decline in the past year. Participants must be able to swallow pills and give consent. Excluded are pregnant or breastfeeding individuals, those on anticoagulants or immunosuppressants, cancer patients, non-English speakers, and anyone with severe health issues affecting survival beyond a year.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Pharmacokinetic (PK) Phase
Establishing a safe dose of 4 tablets once daily in participants with CKD Stages 3 - 4
Treatment
Participants receive either Avmacol ES or placebo in a randomized, double-blind manner
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Sulforaphane (Avmacol Extra Strength)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Rochester
Lead Sponsor
Nutramax Laboratories, Inc.
Industry Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator
University of Virginia
Collaborator